文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

根治性前列腺切除术后生化复发人群挽救性放疗的应用情况

Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-01-23

研究前瞻性随访了2012至2016年间在密歇根泌尿外科质量改进协作组33家机构接受根治性前列腺切除术的局限期前列腺癌患者,其中1010例术后PSA可检测者中29.5%接受了挽救性放疗。校正患者与机构因素后,各机构间挽救性放疗使用率仍存在显著差异(7%至73%,P<.001)。

要点

  • 术后PSA可检测的1010例患者中,29.5%接受了挽救性放疗。
  • 切缘阳性、更高T分期和更高分级分组与接受挽救性放疗相关(P<.05)。
  • 校正患者因素后各机构挽救性放疗使用率仍从7%到73%不等(P<.001)。

核心结论

  • 术后PSA可检测的前列腺癌患者中挽救性放疗使用率较低,且机构层面使用率差异显著,不能仅用患者因素解释。
  • 提示更高风险疾病的因素(切缘阳性、更高T分期、更高分级分组)是接受挽救性放疗的预测因素。
  • 作者认为这些数据支持扩大挽救性放疗的应用,尤其是在使用率低的机构。

研究设计与样本

  • 前瞻性随访研究,纳入2012至2016年密歇根泌尿外科质量改进协作组33家机构中接受根治性前列腺切除术的局限期前列腺癌患者。
  • 纳入标准为术后至少1次PSA≥0.1 ng/mL且首次可检测PSA后随访≥6个月,排除接受辅助放疗者,共1010例符合条件。
  • 分析挽救性放疗使用情况及其与临床和病理特征的关系。

主要发现

  • 1010例术后PSA可检测患者中29.5%接受了挽救性放疗。
  • 接受挽救性放疗的患者中46.9%在达到PSA≥0.2 ng/mL时或之前已接受治疗。
  • 30.6%的患者在未接受挽救性放疗前PSA已达≥0.5 ng/mL,该组中42.1%后来接受了挽救性放疗。
  • 校正患者与机构层面因素后,切缘阳性、更高T分期和更高分级分组均与接受挽救性放疗相关(P<.05)。
  • 校正患者与肿瘤特征后,各机构校正后挽救性放疗使用率仍存在显著差异,从7%(95%CI 3%-17%)到73%(95%CI 45%-90%,P<.001)。

关键数值与推荐

  • 挽救性放疗使用率:1010例中29.5%。
  • 机构校正后挽救性放疗使用率范围:7%(95%CI 3%-17%)至73%(95%CI 45%-90%,P<.001)。
  • 切缘阳性、更高T分期、更高分级分组与接受挽救性放疗相关(P<.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For men with biochemical recurrence after radical prostatectomy (RP), salvage radiation therapy (SRT), especially "early" SRT (PSA level ≤0.5 ng/mL), is a potentially curative option; however, its utilization is not well defined. We sought to determine factors associated with SRT utilization as well as variation in its administration. MATERIALS AND METHODS: Patients with localized prostate cancer undergoing RP at 33 practices participating in the statewide Michigan Urological Surgery Improvement Collaborative between 2012 and 2016 were prospectively followed. Eligible patients had at least 1 post-RP PSA level ≥0.1 ng/mL with ≥6 months of follow-up after the first detectable PSA level. Patients undergoing adjuvant radiation therapy were excluded. SRT utilization and clinical and pathologic patient characteristics were examined. RESULTS: Of 1010 eligible patients with a detectable PSA level, 29.5% underwent SRT. Of patients who received SRT, 46.9% either reached a PSA ≥0.2 ng/mL or were treated before reaching that PSA level. A total of 30.6% of patients had a PSA level ≥0.5 ng/mL without undergoing prior SRT; of this group, 42.1% later received SRT. After adjusting for patient and practice level factors, positive surgical margins, higher T stage, and higher grade group were all associated with receipt of SRT (P < .05). Even after adjusting for patient and tumor characteristics, significant variation remained in the adjusted rate of SRT utilization across practices sites, ranging from 7% (95% confidence interval, 3%-17%) to 73% (95% confidence interval, 45%-90%, P < .001). Practices were grouped into tertiles based on SRT utilization, and those practices that used SRT more frequently overall were more likely to administer SRT across all patient-based predictors of SRT utilization. CONCLUSIONS: SRT utilization is low among men with a detectable post-RP PSA level, with significant variation in practice-level SRT utilization that cannot be explained by patient factors alone. Factors suggesting higher-risk disease were predictors of SRT administration. These data support the potential to expand the use of SRT, particularly among sites with low utilization.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hawken SR, Spratt DE, Qi J, et al. Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy. Int J Radiat Oncol Biol Phys. 2019. PMID: 30682490. doi:10.1016/j.ijrobp.2019.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。